The Impact of Osteopontin Gene Variations on Multiple Sclerosis Development and Progression

Table 3

Frequency distribution of different outcomes in MS patients carrying different OPN genotypes.

Outcome	Genotypes
	+1239A > C		−156GG > G		+1239A > C
					−156G > GG
	AA	C	GG/GG	G	AA	C
					GG/GG	G
Fast progressive^b	57 (20)	127 (37)	18 (27)	166 (30)	3 (5)	181 (32)
Slow progressive^a	228^c (80)	216 (63)	58 (73)	386 (70)	57 (95)	387 (68)
	𝑃<0.0001^d		𝑃=0.311		𝑃<0.0001
Benign MS^a	110 (38)	84 (24)	36 (46)	158 (28)	35 (52)	159 (28)
Non benign MS^b	183 (62)	263 (76)	42 (54)	404 (72)	32 (48)	414 (72)
	𝑃=0.0001		𝑃=0.0018		𝑃=0.0002

^aPatients displaying RR form (slow progressive) or EDSS ≤ 3 (benign MS) after 10 years from onset.
^bNumber of patients displaying that disease status; proportions are shown in brackets.
Patients displaying either RR course and less than 10 years of followup (29/728) or PP course (71/728) were excluded from the analysis of progression. Patients displaying EDSS ≤ 3.0 and less than 10 years of followup (88/728) were excluded from the analysis of disability.
^cPatients switching to SP form (fast progressive) or reaching EDSS > 3 (non-benign MS) within 10 years from onset.
^dStatistical analysis was performed by comparing the different outcomes with the 𝜒² test.
Total number in the analysis of progression: 628 patients: 285 AA; 343 non-AA; 76 GG; 552 non-GG; 60 AAGG; 568 non-AAGG.
Total number in the analysis of course 640 patients: 293 AA, 347 non-AA; 78 GG, 562 non-GG; 67 AAGG, 573 non-AAGG.